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Abstract
Background: Painful Diabetic Neuropathy (PDN) affects more than 25% of patients with type 2 diabetes; however,
the pathogenesis remains unclear due to lack of knowledge of the molecular mechanisms leading to PDN. In our
current study, we use an animal model of type 2 diabetes in order to understand the roles of p38 in PDN.
Previously, we have demonstrated that the C57BLK db/db (db/db) mouse, a model of type 2 diabetes that carries
the loss-of-function leptin receptor mutant, develops mechanical allodynia in the hind paws during the early stage
(6-12 wk of age) of diabetes. Using this timeline of PDN, we can investigate the signaling mechanisms underlying
mechanical allodynia in the db/db mouse.
Results: We studied the role of p38 in lumbar dorsal root ganglia (LDRG) during the development of mechanical
allodynia in db/db mice. p38 phosphorylation was detected by immunoblots at the early stage of mechanical
allodynia in LDRG of diabetic mice. Phosphorylated p38 (pp38) immunoreactivity was detected mostly in the small-
to medium-sized LDRG neurons during the time period of mechanical allodynia. Treatment with an antibody
against nerve growth factor (NGF) significantly inhibited p38 phosphorylation in LDRG of diabetic mice. In addition,
we detected higher levels of inflammatory mediators, including cyclooxygenase (COX) 2, inducible nitric oxide
synthases (iNOS), and tumor necrosis factor (TNF)-a in LDRG neurons of db/db mice compared to non-diabetic db
+ mice. Intrathecal delivery of SB203580, a p38 inhibitor, significantly inhibited the development of mechanical
allodynia and the upregulation of COX2, iNOS and TNF-a.
Conclusions: Our findings suggest that NGF activated-p38 phosphorylation mediates mechanical allodynia in the
db/db mouse by upregulation of multiple inflammatory mediators in LDRG.
Background
Diabetic neuropathy affects up to 50% of patients with
either type 1 or type 2 diabetes [1,2]. Among the multi-
ple symptoms of diabetic neuropathy, painful diabetic
neuropathy (PDN) is the most devastating complication
of diabetes [3]. Although there are multiple presenta-
tions of PDN in diabetic patients, the most common
symptoms of PDN result from a length-dependent poly-
neuropathy starting at the longest axonal terminals in
the feet and extending toward the body [3]. The upper
extremities become affected in a similar fashion as the
disease progresses, eventually forming the characteristic
glove and stocking distribution of sensory symptoms
[1,2]. It is believed that PDN is an early component of
diabetic neuropathy [4,5]. PDN is detected more
frequently in patients with prediabetic condition or
impaired glucose tolerance than in patients with late-
stage diabetes [5]. Similar to other types of neuropathic
pain, PDN has features of allodynia and hyperalgesia [6].
Allodynia is defined as increased nociceptive perception
to normally innocuous stimuli and hyperalgesia indicates
increased nociception to normally painful stimuli.
Although PDN is a common symptom among diabetic
patients, its mechanisms remain unclear. Current treat-
ments for PDN are not effective and less than 30% of
patients obtain satisfactory pain relief [6].
Mitogen activated protein kinases (MAPK) are a
group of intracellular messenger proteins that transmit
signals from cell membrane receptors to the nucleus.
The MAPK family consists of extracellular signal-regu-
lated protein kinases (ERKs), p38, and c-Jun N-terminal
kinase (JNK). All MAPKs are involved in both inflam-
matory and neuropathic pain [7,8]. However, individual
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els [8]. p38 is a serine-threonine kinase which is acti-
vated by phosphorylation and mediates many cellular
responses to a variety of chemical and physical insults
[9]. In a model of NGF-induced hyperalgesia, p38
is phosphorylated in Trk A-positive small to medium-
sized dorsal root ganglian (DRG) neurons and phos-
phorylated p38 (pp38) mediates NGF-induced
upregulation of nociceptive molecules [10]. In addition,
peripheral inflammation and axotomy also activate p38
in both DRG neurons and spinal cord microglia [11-13].
Administration of a p38 inhibitor, SB203580, reverses
p38-mediated pain in several pain models [9,14]. Inhibi-
tion of p38 activation prevents the development of PDN
in streptozotocin (STZ)-treated animal models of type 1
diabetes [14].
PDN is more prevalent in type 2 than type 1 diabetes
[6], yet most published studies for PDN use animal
models of type 1 diabetes. Understanding the mechan-
isms of PDN as it develops in the context of type 2 dia-
betes could lead to developments of effective treatments
to target this devastating disease. We have previously
characterized the db/db mouse as a model for PDN of
type 2 diabetes [15]. The db/db mouse carries a homo-
zygous null mutation of the leptin receptor [16,17]. We
reported that db/db mice develop features of PDN,
including mechanical allodynia at 6-12 wk of age and
evident sensory neuropathy at 24 wk of age [15,17]. We
reported that the mechanical allodynia in db/db mice is
concordantly associated increased NGF/Trk A receptor
signaling in DRG neurons. In the current study, we
examine the roles of p38 in the development of
mechanical allodynia in db/db mice. We hypothesized
that NGF-Trk A signaling could trigger p38 activation
and upregulate p38-depedent nociceptive molecules in
LDRG of db/db mice. Our findings provide new under-
standing of the molecular mechanisms of PDN of type 2
diabetes and indicate that p38 could be a potential tar-
get for treating PDN of type 2 diabetes.
Results
p38 is phosphorylated during the time period of
mechanical allodynia
We previously detected the development of mechanical
allodynia in db/db mice from 6-12 wk of age. The
maximum reduction of mechanical pain thresholds was
detected at 8 wk of age [15]. In the current study,
pp38 immunoblots were performed on LDRG collected
at 5, 8, 10, and 12 wk of age (Fig. 1). Representative
pp38 immunoblots demonstrated increased phosphory-
lation of p38 in LDRG of the db/db mouse model in
comparison to the db+ mouse model at 5, 8 and 10 wk
of age. At 12 wk of age, p38 phosphorylation in db/db
mice was reduced to the control level (Fig. 1A). There
was no difference in levels of total p38 protein expres-
sion between db+ and db/db mice. Densitometric stu-
dies which normalized the levels of pp38 to that of
total p38 and actin revealed significantly increased p38
phosphorylation in the db/db mouse at 5, 8, and 10 wk
of age. No significant difference between the pp38
levels of db+ and db/db mice was detected at 12 wk of
age (Fig. 1B).
pp38 immunoreactivity is detected in small- to
medium-sized LDRG neurons during the time period of
mechanical allodynia
We next localized pp38 in L4-6 DRG using immunohis-
tochemistry (Fig. 2). Only trace amounts of pp38 immu-
noreactivity were detected in L4-6 DRG of db+ mice
(Fig. 2A, arrowhead). In L4-6 DRG of db/db mice, pp38
immunoreactivity was detected mostly in the nuclei of
small- to medium-sized neurons (Fig. 2B, arrow). Quanti-
fication studies demonstrated that there is a significant
increase in the percentage of pp38-positive neurons in
db/db mice compared to db+ mice of the same age dur-
ing the period of mechanical allodynia (Fig. 2C). The
most prominent increase was detected at 8 wk of age,
with a 6-fold increase in the percentage of pp38-positive
neurons in db/db mice in comparison to db+ mice. A cell
size distribution study detected significant increases of
not only the percentages of pp38 positivity in small-
(<20 μm in diameter) to medium-sized (20-40 μmi nd i a -
meter) LDRG neurons, but also in large-sized (>40 μmi n
diameter) LDRG neurons in db/db mice at 8 wk of age
(Fig. 2D).
Anti-NGF inhibits the phosphorylation of p38 in
db/db mice
Previously, we reported enhanced NGF expression and
phosphorylation of Trk A receptors in LDRG of db/db
mice during the period of mechanical allodynia. The
time course of NGF-Trk A signaling parallels the cur-
rent findings of p38 phosphorylation [15]. To investigate
if NGF is an upstream activator of p38 during the
period of mechanical allodynia in db/db mice, we admi-
nistered the same anti-NGF antibody used in our
previous studies to block the development of mechanical
allodynia [15]. Pp38 immunoblots were performed to
determine the effects of anti-NGF on p38 phosphoryla-
tion in LDRG following 2 weeks of anti-NGF treatment,
following the same paradigm as our previous studies
[15]. Treatments with anti-NGF at 6 and 7 wk of age
significantly decreased the phosphorylation of p38 in
LDRG of db/db mice at 8 wk of age (Fig. 3A). Densito-
metric studies further determined that anti-NGF
reversed the p38 phosphorylation in db/db mice but did
not affect the baseline p38 phosphorylation in LDRG of
db+ nondiabetic mice (Fig. 3B).
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phosphorylation and mechanical allodynia
To determine directly if the activation of p38 mediates
mechanical allodynia in db/db mice, a p38 inhibitor,
SB203580, was administered intrathecally via mini
osmotic pumps. Minipumps were inserted into both
db+ and db/db mice at 7 wk of age and delivered
SB203580 in artificial CSF with 10% DMSO at a rate of
0.51 μg/hr for 7 d. Control groups were treated with
artificial CSF with 10% DMSO. Mechanical thresholds
were measured at the end of the SB203580 treatment.
pp38 immunoblots confirmed the inhibition of p38
phosphorylation in LDRG in response to SB203580
treatment in both db+ and db/db mice (Fig. 4A). Densi-
tometric analysis demonstrated a reversal of p38 phos-
phorylation in db/db mice down to the levels observed
in the control db+ mice (Fig. 4B). In conjunction with
the inhibition of p38 phosphorylation, SB203580 treat-
ment inhibited mechanical allodynia in db/db mice
(Fig. 4C) and lowered the percentage of substance P
(SP)-positive neurons (Fig. 4D). In contrast, the percen-
tage of Isolectin B-4 (IB4)-labeled neurons was not
affected by SB203580 treatment (Fig. 4E).
Intrathecal administration of SB203580 inhibits the
upregulation of inflammatory mediators in LDRG of
db/db mice
To study the downstream molecules of NGF-p38 signal-
ing, we screened several nociceptive molecules reported to
be involved in p38-mediated pain, including COX2, iNOS,
and TNF-a. We first performed RT-PCR to measure the
gene expression of these molecules (Fig. 5). Similar
patterns of gene regulation were detected for all three
proteins. The gene expression of COX2 (Fig. 5A), iNOS
(Fig. 5B), and TNF-a (Fig. 5C) were all upregulated in
LDRG of db/db mice in comparison to the db+ control.
SB203580 treatment significantly decreased the upregula-
tion of all three genes (Fig. 5A-C). SB203580 treatment
did not affect the gene expression of these molecules in
LDRG of db+ mice except in the case of TNF-a (Fig. 5C).
To determine the cellular localization of the p38-
dependent inflammatory mediators in LDRG, immuno-
histochemistry studies were performed for iNOS
( F i g .6 A ,B ,C ,D ) ,T N F - a (Fig. 6E, F, G, H), CD68 (a
m a c r o p h a g em a r k e r ,F i g .6 I ,6 J ,6 K ,6 L ) ,a n dC O X 2( F i g .
6M, N, O, P). Both db+ and db/db mice were treated
with vehicle or vehicle containing SB203580 intrathecally
for 1 wk. Enhanced immunoreactivity for iNOS, TNF-a
and COX2 was detected in LDRG of db/db mice when
compared to LDRG of db+ mice. The immunopositive
cells for iNOS, TNF-a,a n dC O X 2a r em o s t l yn e u r o n s ,
and include both small- to medium- and large sizes (Fig.
6C, G, K, O). In addition, increased numbers of CD68-
positive macrophages were detected in db/db mouse
LDRG, suggesting the involvement of cell-mediated
inflammation (Fig. 6K). SB203580 treatment significantly
reduced the immunoreactivity of iNOS, TNF-a, CD68,
and COX2, in DRG neurons of db/db mice (compare Fig.
6C to 6D, G to 6H, K to 6L, and 6O to 6P).
We further quantified the numbers of immunopositive
LDRG neurons of db+ and db/db mice treated with
vehicle control and SB203580 for iNOS (Fig. 7A), COX2
Figure 1 Phosphorylation of p38 during the course of mechanical allodynia. A: Representative immunoblots of pp38, p38 and GAPDH
using LDRG extracts from db+ and db/db mice at 5, 8, 10, and 12 wk of age. Increased levels of pp38 were detected in db/db mice when
compared to db+ mice at 5, 8 and 10 wk of age. At 12 wk of age, p38 phosphorylation returned to the control level. In addition, no change in
expression levels of p38 was detected in LDRG of db/db mice and db+ mice. GAPDH served as the loading control. B: Densitometric analysis of
immunoblots using LDRG of db+ and db/db mice at 5, 8, 10 and 12 wk of age during the development of mechanical allodynia. Significantly
enhanced pp38 levels were detected in db/db mice at 5, 8 and 10 wk of age but not at 12 wk of age. N = 4, *p < 0.05.
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Page 3 of 14Figure 2 pp38 immunohistochemistry in LDRG of db+ and db/db mice. A, B: Representative pictures of pp38 immunohistochemistry in DRG
from db+ (A) and db/db (B) mice at 8 wk of age. Increased nuclear immunoreactivity was detected in db/db (arrow) but not db+ (arrowhead)
LDRG neurons. Bar = 15 μm. C: Quantitation of pp38-positive LDRG neurons in db+ and db/db mice. Significantly increased numbers of pp38-
positive LDRG neurons were detected in db/db mice in comparison with db+ mice. N = 6, *p < 0.05, **p < 0.01. At 8 wk of age, the maximum
increase in the percentage of pp38-positive neurons was detected in comparison to 5 and 10 wk LDRG. *p < 0.05, one-way ANOVA test. D: Cell
size distribution of pp38-positive LDRG neurons at 8 wk of age. Significant increase of pp38-positive LDRG neurons were detected in neurons
<20 μm, 20-30 μm and 30-40 μm in diameter. Small numbers of large DRG neurons (<40 μm) were also positive for pp38 in db/db mice but
not db+ mice. N = 4, *p < 0.05.
Figure 3 Anti-NGF treatment inhibits the phosphorylation of p38 in db/db mice. A: Representative immunoblots of pp38, p38 and actin
using LDRG from db+ and db/db mice treated with either control (IgG) or an anti-NGF antibody for 2 wk. Anti-NGF treatment decreased the
intensity of pp38 signals in db/db mice but not db+ mice at 8 wk of age. B: Densitometric studies of pp38 immunoblots using LDRG from 8 wk
old db+ and db/db mice. A significant decrease in p38 phosphorylation was detected in db/db mice after anti-NGF treatment. N = 4, **p < 0.01.
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Page 4 of 14Figure 4 SB203580 inhibits p38 phosphorylation, mechanical allodynia, and the percentage of SP-positive LDRG neurons in db/db
mice. A: Representative immunoblots of pp38, p38 and actin from db+ and db/db LDRG at 8 wk of age after 1 wk of intrathecal treatments of
vehicle (control CSF with 10% DMSO) (C) or vehicle with SB203580. SB203580 treatment decreased levels of p38 phosphorylation in db/db mice
but not in db+ mice. B: Densitometric studies of pp38 immunoblots demonstrated significant inhibition of p38 phosphorylation in db/db mice.
C: SB203580 treatment reversed the decrease in mechanical thresholds (allodynia) in db/db mice. D: SB203580 treatment also lowered the
elevated percentages of SP-positive LDRG neurons in control db/db mice compared to control db+ mice. E: SB203580 treatment had no effect
on the percentage of IB4-labelled LDRG neurons in db+ and db/db mice. N = 4, **p < 0.01.
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Page 5 of 14(Fig. 7B), and TNF-a (Fig. 7C). Increased percentages of
neurons positive for all three molecules in db/db mice
were observed in comparison to db+. In db/db mice,
SB203580 significantly decreased the percentages of
COX2, iNOS, and TNF-a positive LDRG neurons.
Immunoblots of COX2, iNOS, and TNF-a (Fig. 8A)
were performed in order to quantify the levels of these
inflammatory proteins. Densitometric analysis confirmed
that the levels of COX2 (Fig. 8B), iNOS (Fig. 8C) and
TNF-a (Fig. 8D) were increased in db/db mice in com-
parison to levels detected in db+ mice. SB203580 treat-
ment inhibited this upregulation of inflammatory
protein expression. However, in contrast to what is
observed in db/db mice, SB203580 treatment did not
have an effect on the protein levels of db+ mice (Fig. 8).
Discussion
P38 has been reported to mediate many types of pain
[7]. Here we are the first to report a role for this protein
kinase in mechanical allodynia associated with PDN in
an animal model of type 2 diabetes. Previously, we
reported that NGF-Trk A signaling is elevated in db/db
mice [15]. The current study focuses on the mechanism
underlying this role of p38 kinase in PDN and demon-
strates that p38 is phosphorylated via NGF signaling in
DRG neurons in the type 2 diabetic model. In turn,
NGF-mediated p38 phosphorylation leads to mechanical
allodynia in the db/db mouse by upregulation of multi-
ple inflammatory mediators in LDRG.
Our results demonstrated the phosphorylation of p38
in DRG of db/db mice at the early stage of mechanical
allodynia. P38 phosphorylation was transient (from 5-10
wk) and in parallel with the increased NGF expression
in DRG and the development of mechanical allodynia
[15]. The cause of this p38 phosphorylation is unclear,
although the effect appears to result from exposure to
hyperglycemia. We previously found that p38 is acti-
vated in neurons in culture in high glucose conditions
Figure 5 SB203580 inhibits the upregulation of COX2, iNOS and TNF-a gene expression. RT-PCR analysis of COX2 (A), iNOS (B) and TNF-a
(C) in LDRG of db+ and db/db mice. The gene expression of all three inflammatory mediators was upregulated in LDRG of db/db mice.
SB203580 treatment significantly decreased the elevated levels of gene expressions in db/db mice. In addition, SB203580 treatment lowered the
gene expression of TNF-a in db+ mice. N = 4, *p < 0.05.
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Page 6 of 14[18]. Phosphorylation of p38 is also reported in other
tissues of db/db mice [19]. Adhikary and colleagues
detected p38 activation in kidneys of mouse models of
type 1 and type 2 (db/db) diabetes, as well as kidneys of
diabetic patients. Levels of pp38 in kidneys increased
(2-6 fold) following the onset of diabetes in interstitial
macrophages and myofibroblasts of db/db mice in a
manner that was associated with increased NGF expres-
sion downstream of hyperglycemia, and increased HbA
(1)c. Our results demonstrate a comparable time course
of p38 phosphorylation in DRG, suggesting similar
mechanisms could be involved in the neuronal systems.
In the current study, the p38 phosphorylation in DRG
of db/db mice returned to the control levels at 12 wk of
age. This reduction is likely a result from lack of NGF
support at this stage [15]. Future studies using anti-dia-
betic agents will elucidate the role of hyperglycemia in
the phosphorylation of p38 in DRG of db/db mice.
Our findings of p38 phosphorylation parallel reports
in a variety of inflammatory painful conditions, includ-
ing osteoarthritic pain [20], bone pain [21], and com-
plete Freund’s adjuvant-induced inflammatory pain [22].
Figure 6 Immunolocalization of iNOS, TNF-a, CD68, and COX2. Immunohistochemistry studies were performed on LDRG of db+ (A, B, E, F, I,
J, M, N ) and db/db mice (C, D, G, H, K, L, O, P). The mice were treated with vehicle control (A, C, E, G, I, K, M, O) or vehicle with SB203580 (B, D,
F, H, J, L, N, P). In vehicle control treated mice, an increased percentage of iNOS-positive DRG neurons were detected in both large (arrow) and
small to medium (arrowhead)-sized DRG neurons in db/db (C) in comparison with db+ (A) mice. Double immunofluorescent studies
demonstrated that TNF-a immunoreactivity was detected in the iNOS-positive neurons of db/db mice (G) with minimal immunoreactivity
detected in db+ mice (E). In LDRG of db/db mice, many CD68-positve macrophages were detected but not in db+ LDRG (compare K and I,
arrows). COX-2 expression was also detected in both small and large neuronal populations (O, arrowhead and arrow respectively) in db/db but
not db+ mice. SB 203580 treatment did not change the patterns of immunoreactivity of iNOS, TNF-a, CD68, and COX2 in db+ mice (compare A
to B, E to F, I to J, and M to N). In comparison, SB203580 treatment significantly decreased the immunoreactivity of iNOS, TNF-a, CD68 and
COX2 in LDRG of db/db mice (compare C to D, G to H, K to L, and O to P). N = 4, Bar = 30 μm.
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many neuropathic painful conditions, including nerve
injury [13,23], neuropathic pain from type 1 diabetes
[24], and central pain syndromes [25]. In the peripheral
nervous system, p38 is activated in primary sensory
DRG neurons by noxious stimuli [26], inflammatory
pain [10,27] and nerve injuries [28,29].
In the current study, we found that p38 is phosphory-
lated in small- to medium- sized LDRG neurons during
the period of mechanical allodynia in db/db mice. Our
findings are consistent with those of the STZ model of
type 1 diabetic pain [14,24], Obata and colleagues
reported that most pp38 immunoreactivity is detected in
small to medium-sized neurons, which also corresponds
with our findings. [26,29]. In the spinal cord of similar
pain models, pp38 immunoreactivity is detected in
microglia, secondary sensory neurons, and astrocytes [7].
We demonstrate that NGF is an important factor to
induce p38 activation in db/db mice. Anti-NGF treatment
completely blocked p38 phosphorylation in LDRG in db/
db mice and subsequent mechanical allodynia. NGF acti-
vates p38 in primary DRG neurons [10,30]. It has been
proposed that NGF-activated p38 could increase the
expression of transient receptor potential vallinoid (TRPV)
1 receptor [10] and transient receptor potential subfamily
A 1 receptor [30] to mediate thermal and cold hyperalge-
sia respectively. According to Puntambekar and Mukher-
jea, the p38-mediated TRPV1 upregulation is secondary to
activation of the Trk A receptor and its downstream
RAC1/NADPH oxidase pathway [31]. The consistent time
course shared by p38 phosphorylation, NGF upregulation,
and Trk A phosphorylation in LDRG strongly suggests
that the NGF-Trk A/p38 pathway mediates mechanical
allodynia in db/db mice [15].
Figure 7 SB203580 treatment decreases the expression of iNOS, COX2, and TNF-a in db/db LDRG neurons. The percentages of
immunopositive LDRG neurons for iNOS (A), COX2 (B), and TNF-a (C) were measured in db+ and db/db mice. The mice were treated with
vehicle control (artificial CSF containing 10% DMSO) or vehicle with SB203580. Significant increases in the percentages for iNOS, COX2, and TNF-
a were detected in vehicle-treated db/db mice, in comparison to db+ mice. SB203580 treatment significantly blocks the increased percentages
of iNOS, COX2, and TNF-a in db/db mice to levels comparable with the nondiabetic control (db+) mice. N = 4, ***p < 0.001.
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administration of SB203580 completely blocks p38
phosphorylation and mechanical allodynia. Intrathecal
administration of SB203580 blocks p38 phosphorylation
in both DRG neurons and spinal cord cells (including
neurons, astrocytes and microglia), according to pre-
vious studies [13,14,32,33]. In addition, other p38 inhibi-
tors are used with the same result [24]. One caveat to
our approach and that of our colleagues is that intrathe-
cal administration of p38 inhibitors prevents p38 activa-
tion in both central and peripheral areas of the nervous
system, thus the roles of site-specific p38 activation can-
not be determined using this approach. As a result, we
cannot eliminate the hypothesis that inhibitory effects of
SB203580 on the development of PDN could result
from effects in the spinal cord. Regardless, our findings
support the use of p38 inhibitors for treating PDN of
type 2 diabetes. Future studies should address the dis-
tinct roles of central versus peripheral p38 activation in
PDN of type 2 diabetes.
We demonstrate that p38-mediated mechanical allody-
nia in db/db mice is primarily mediated by small to
medium-sized LDRG neurons that are immunopositive
for SP. We previously reported that these SP-positive
neurons are NGF-positive neurons with Trk A receptors
[15]. Thus, our current results support the current
hypothesis that NGF-dependent neurons are primarily
responsible for the development of allodynia. In con-
trast, the numbers of IB4-labelled neurons are not
affected in db/db mice, suggesting that GDNF depen-
dent neurons do not play a role in mediating mechani-
cal allodynia in db/db mice. These results are consistent
with our previous findings that GDNF expression and
the percentages of IB4-labelled neurons do not change
in db/db mice [15]. In parallel with our findings, NGF,
but not GDNF-sensitive neurons, mediate discogenic
pain [34]. According to Ramer and Bradbury, intrathecal
injection of NGF treatment induces more extensive
expression of the P2X3 receptor than GDNF in both
DRG and spinal cord dorsal horn, and leads to chronic
Figure 8 SB203580 treatment inhibits protein expression of inflammatory mediators in db/db mice. A: Representative immunoblots of
LDRG from db+ and db/db mice. After 1 wk treatments with vehicle control or vehicle with SB203580, immunoblots were performed for iNOS,
COX2, and TNF-a. Increased protein levels for all three inflammatory mediators were demonstrated in LDRG of db/db mice compared to db+
littermates. This upregulation was inhibited by treatment with SB203580. Actin served as a loading control. B, C, D: Densitometric analysis of
COX2 (B), iNOS (C), and TNF-a (D) demonstrated significant upregulation of each respective protein in db/db mice that is inhibited by SB203580.
N = 4, *p < 0.05, **p < 0.01.
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Page 9 of 14pain [35]. The upregulation of SP-positive neurons in
our current study is reduced by SB203580, supporting
our contention that p38 mediates SP-upregulation in
the DRG of db/db mice. There are two potential signal-
ing mechanisms that may underlie this effect: 1) NGF
may directly induce Trk A-dependent p38 phosphoryla-
tion, or 2) NGF could indirectly activate interleukin 1-
beta-dependent p38 activation to promote SP expression
[36]. We are currently performing experiments to distin-
guish between these two possibilities.
Our findings suggest that there are inflammatory reac-
tions that occur in DRG of type 2 diabetes. Specifically,
we detected increasing macrophage infiltration as well
as upregulation of multiple inflammatory mediators in
LDRG of db/db mice. Joachim and colleagues deter-
mined that NGF, a proinflammatory cytokine, induces
inflammation in multiple tissues, including skin [37]. It
is known that NGF administration to skin not only
induces an inflammatory reaction but also increases the
number of dermal SP and CGRP-positive nerve fibers.
Previously, we have reported that there is increased
NGF expression in dermal inflammatory cells and nerve
fibers in db/db mice, indicating that similar NGF-
mediated inflammation occurs in the skin of mice with
type 2 diabetes [15]. Our current study provides further
evidence that similar inflammation occurs in DRG of
db/db mice.
Our study demonstrated an upregulation of COX2
expression in DRG of db/db mice. Kellogg et al reported
increased COX2 expression in DRG of STZ rats, a
model of type 1 diabetes and suggested potential roles
of COX2 in the mediation of diabetic neuropathy, which
is consistent with our findings [38]. COX2 also mediates
other diabetic complications, including nephropathy
[39]. In order to study COX2, Bujaslska et al used speci-
fic COX2 inhibitors to demonstrate that COX2 mediates
hyperalgesia in the STZ model of type 1 diabetes. [40].
Our study demonstrates that COX2 expression is
mediated by p38 in the DRG of db/db mice. In support
of our findings, Amaya and colleagues reported a p38-
dependent COX2 expression by IL-1 [27]. In contrast,
Kitazawa et al demonstrated that C-peptide-induced
COX2 upregulation is dependent on the PKC/IkappaB/
NF-kappaB signaling pathway in fibroblasts [41]. We
acknowledge that there are multiple signaling mechan-
isms to regulate COX2 expression and at this time we
can not exclude the PKC/IkappaB/NF-kappaB signaling
pathway, which could be an upstream or downstream
mechanism of p38 activation to increase COX2
expression.
We detected increased iNOS expression in DRG of
db/db mice and suggest this upregulation could be a
mechanism of mechanical allodynia. In agreement with
our hypothesis, iNOS knockout mice have increased
resistance to diabetic neuropathic complications, includ-
ing impaired nerve conduction velocities and small fiber
sensory neuropathy, indicating that iNOS could be an
important mediator of PDN [42]. There is evidence to
imply that diabetes-induced increased NO levels result
from cellular signaling via advanced glycation and lipox-
idation end products (AGEs/ALEs) [43]. The increased
NO levels likely contribute to tactile hyperalgesia in the
STZ model of type 1 diabetes [44]. In support of our
findings in type 2 diabetes, Bujalska et al reported that
intrathecal administration of a specific inhibitor of
iNOS, but not neuronal NOS, prevents hyperalgesia in
STZ-induced type 1 diabetes [40].
We report that there is a p38-dependent TNF-a upre-
gulation in DRG of db/db mice. Sherry et al demonstrate
that p38 also mediates augmented lipopolysaccharide
induced TNF-a expression in peritoneal macrophages of
d b / d bm i c e[ 4 5 ] .I nc o n t r a s tt ot h e i rf i n d i n g s ,w e
detected increased DRG expression of TNF-a in neurons
instead of in infiltrating macrophages. However, macro-
phages could contribute to both inflammation and pain
by increasing interleukins in DRG, including, IL-6 [46],
and IL-12 [47]. Our findings strongly suggest that NGF
increases TNF-a expression via p38. However, other
NGF-dependant signaling mechanisms have been
reported to enhance TNF-a expression, including NF-
kappaB. In support of our results, neuronal-derived
TNF-a expression is upregulated in DRG of nerve injury
models [48,49]. One way that TNF-a could increase
mechanical nociception is by activating p38 via the TNF
receptor 1 to modulate the tetrodotoxin-resistant sodium
channel in DRG [50]. This molecular mechanism could
also occur in our model with elevated neuronal p38-
mediated-TNF-a expression which, in turn, could serve
as an autocrine factor to cause secondary p38 activation
via the cell surface TNF receptor 1. The gene expression
of TNF-a was decreased by SB203580 in db+ mice. In
contrast, SB203580 did not alter COX2 or iNOS RNAs.
The finding suggests that there is a baseline
p38-mediated regulation of TNF-a expression. Baseline
p38-mediated TNF-a m a yb er e g u l a t e db yt h et r i v i a l
NGF level in LDRG of control mice or via other pathways
like IL-b inhibition of G protein-coupled receptor kinase
2 (GRK2) [51].
In summary, the current study demonstrates the phos-
phorylation of p38 and the upregulation of multiple
inflammatory mediators including COX2, iNOS, and
TNF-a in DRG neurons of db/db mice. Our data sug-
gest that inflammation in DRG could mediate mechani-
cal allodynia in type 2 diabetes. While current guidelines
for treating PDN only use neuropathic pain regimens
[52], our results suggest that a combination of both neu-
ropathic and anti-inflammatory therapies that target
COX2, iNOS, and TNF-a will improve the current
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p38 mediates multiple inflammatory mediators in PDN
of type 2 diabetes, clinical studies using p38 inhibitors
could potentially provide a better approach than using
multiple inhibitors for mediators downstream of this
mechanism to alleviate PDN of type 2 diabetes [53].
Methods
Animals
Male C57BLKS db/db mice were purchased from Jack-
son Laboratories (Bar Harbor, Maine; stock number
000662). The homozygous (Lepr
db/ Lepr
db,o rd b / d b )
mice were used as a model of type 2 diabetes, while het-
erozygous mice (Lepr
db/+, or db+) served as nondiabetic
controls. Analyses and procedures were performed in
compliance with protocols established by the Animal
Models of Diabetic Complications Consortium
(AMDCC) http://www.amdcc.org and were approved by
the Use and Care of Animals Committee at the Univer-
sity of Michigan. All possible efforts were made to mini-
mize the animals’ suffering and the number of animals
used.
Mechanical Allodynia
The animals were placed in a Plexiglas cage with mesh
flooring and allowed to acclimate for 1 h. A logarithmic
series of calibrated monofilaments (Von Frey hairs;
Stoelting, Wood Dale, IL) with bending forces from 1 to
10 g were applied to the mid-plantar surface of the hind
paw and pressed to the point of bending. Brisk withdra-
wal of the stimulated paw was recorded as a positive
response. Testing began with the 1 g filament, followed
by larger filaments if no response was observed, using
the up-down method [54], with a 10 min. interval to
allow the animals to recover between tests. Although all
responses were noted, counting of the critical 6 data
points did not begin until the response threshold was
first crossed. The resulting pattern of the 6 positive and
negative responses was tabulated, and the 50% gram
threshold was calculated using the formula described
previously [55]. Mechanical allodynia was determined by
a significant decrease in the mechanical threshold of the
db/db mouse in comparison to that of a db+ littermate.
Real time RT-PCR
Total RNA was extracted from L4-6 DRG (LDRG) using
the RNeasy Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Six DRG (bilateral L4-6)
were used for each animal and a total of 4 animals were
used per condition. Reverse transcription was performed
using the iScript cDNA Synthesis Kit (BioRad, Hercules,
CA). Briefly, 5× iScript Reaction Mix, 1 μli S c r i p t
Reverse Transcriptase and total RNA template were
added to a final volume of 20 μl. Reaction conditions
were 5 min. at 25°C, 30 min. at 42°C and 5 min. at
85°C. PCR was performed as described previously [56]
using the primer sequences: COX2: sense 5′-GAT GAG
CAA CTA TTC CAA ACC AG, antisense 5′-CCG CTC
AGG TGT TGC ACG TAG; iNOS sense 5′-GGG CAG
CCT GTG AGA CCT T, antisense 5′-TGA GGG CTC
TGT TGA GGT CTA; TNF-a sense 5′-AGC CGA TTT
GCT ATC TCA TAC CAG, antisense 5′-CCT TCA
CAG AGC AAT GAC TCC A; GAPDH sense 5′-TCC
ATG ACA ACT TTG GCA TCG TGG-3′,a n t i s e n s e5 ′-
GTT GCT GTT GAA GTC ACA GGA GAC-3′.
All real-time PCR reactions were carried out in 96-
well PCR plates sealed with iCycler Optical Sealing Tape
(BioRad). The PCR reactions contained 1× SYBR Green
iCycler iQ mixture (BioRad), 0.2 μM of each forward
and reverse primer, and cDNA preparation to 25 μl
total volume. The PCR amplification profile was 94°C
for 2 min, 35 cycles of denaturation at 94°C for 30 s,
annealing at 60°C for 1 min, and extension at 72°C for
30 s, followed by 72°C for 5 min. The mRNA expression
levels of the genes were tested, and amplification and
fluorescence detection were performed using iCycler iQ
Real-time Detection System (BioRad). At the end of the
PCR, melting curves were obtained from 46 subsequent
temperature increments by measuring fluorescence
every 10 s with + 0.5°C/step increment, beginning at
72°C. The quality of PCR products was determined by
melting curve analysis. The fluorescence threshold value
was calculated by the iCycler iQ system software, and
the levels were normalized to values obtained for
GAPDH. A non-template control [57] was run with
every assay.
Immunoblots
Following deep anesthesia, L4-6 DRG were dissected
from 4 mice per condition (db/db and db+) and homo-
genized in ice-cold T-PER Tissue Protein Extraction
Reagent (Pierce Biotechnology, Rockford, IL) contain-
ing protease inhibitors (1 μMs o d i u mo r t h o v a n a d a t e
and 1 μM sodium fluoride; Sigma Life Science, St.
Louis, MO). Lysates were sonicated for 5 s, centrifuged
and processed for protein concentration using DC Pro-
tein Assay Reagents (BioRad). 50 μg of protein were
boiled in 2× sample buffer, separated on a SDS-PAGE
gel, and transferred to a PVDF membrane. Membranes
were blocked and incubated overnight at 4°C with pri-
mary antibodies: phospho-p38 (pp38, 1:1000, rabbit
polyclonal, Cell Signaling, Danvers, MA), total p38
(1:1000, rabbit polyclonal, Cell Signaling Danvers,
MA), COX2 (1:1000, Cayman Chemical, Ann Arbor,
MI), iNOS (1:1000, Abcam Inc, Cambridge, MA), and
TNF-a ( 1 : 1 0 0 0 ,A b c a m ,C a m b r i d g e ,M A ) .M e m b r a n e s
were then rinsed and incubated with HRP-conjugated
secondary antibodies for 1 h at 25°C and processed
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Scientific, Rockford, IL) before being exposed to
Hyperfilm (Amersham, Piscataway, NJ). Densitometry
was performed using Image J software, and the results
were normalized against actin densities from the same
sample.
Immunohistochemistry
Four mice from each group (db+ and db/db) were dee-
ply anesthetized and perfused with 2% paraformaldehyde
in phosphate buffered saline (PBS, pH 7.2, 0.1 M). L4-L6
DRG were dissected and post-fixed by immersion in 2%
paraformaldehyde overnight at 4°C, then rinsed in
graded sucrose solutions (5-30% in PBS), embedded in
mounting media (OCT), and flash-frozen in liquid nitro-
gen. Tissue sections (10 μm) were cut and mounted
onto SuperFrost Plus slides (Fisher Scientific, Pittsburgh,
PA) and stored at -80°C until ready for use. For immu-
nolocalization, tissue sections were thawed on a warm-
ing plate (55°C for 10 min), hydrated with PBS, and
blocked in 0.1% TX-100 and 5% non-fat dry milk in
PBS. Sections were then incubated at room temperature
for 16-24 h with primary antibodies: pp38 (1:1000), SP
(Rat monoclonal, 1:500, Abcam), iNOS (1:1000), TNF-a
(1:1000), or COX2 (1:1000). Sections were then rinsed 3
times in PBS and incubated with secondary antiserum
conjugated with different fluorophores (AlexaFluor 488,
594, or 647, Invitrogen, Carlsbad, CA). Neurons were
identified using NeuN antibody (1:250, Neuronal Nuclei,
Alexa Fluor 488, Millipore, Temecula, CA). For IB4
labeling studies, the sections were incubated with Alexa-
Fluor 594 labeled Griffonia simplicifolia Isolectin B-4
(1:500, Invitrogen) with 5% non-fat dry milk in PBS for
1 h. Sections were rinsed and mounted with ProLong®
Gold antifade reagent (Invitrogen). To ensure specificity,
sections were incubated with primary or secondary anti-
sera alone to confirm there were no nonspecific immu-
noreactions. Fluorescent signals were examined using an
Olympus FluoView 500 laser scanning confocal
microscope.
The percentage of immunopositive cells was analyzed
by counting the number of immunopositive neurons
and multiplying by (100/total number of neurons). Cell
size distribution studies were performed on the same
image. A total of 6 LDRG from each animal were mea-
sured. Images of LDRG sections were captured with a
Nikon camera (Nikon Microphoto-FXA), and the num-
ber of immunoreactive neuronal profiles was counted in
a blinded fashion. Every tenth section was picked from a
series of consecutive LDRG sections (10 μm), and three
to four sections were counted for each LDRG and
expressed as the percentage o ft o t a ln e u r o n a lp r o f i l e
measured by NeuN immunohistochemistry [10]. Sec-
tions were incubated with primary antisera alone, or
secondary antisera alone, to ensure specificity. No signif-
icant nonspecific immunolabeling was detected in either
control condition.
Anti-NGF treatment
To inhibit NGF action during the period of allodynia,
we administered anti-NGF (10 mg/kg, mouse monoclo-
nal antibody clone AS21, Exalpha Biologicals, Maynard,
MA) or control IgG, intraperitoneally, once weekly to
db+ and db/db mice at 6 and 7 wk of age for 2 wk
[15,58]. L4-6 LDRG were collected at 8 wk of age and
processed for pp38/p38 immunoblots.
Minipump placement
An osmotic minipump (Alzet minipump model 1007D,
Duent Corporation, Cupertino, CA) was used for con-
tinuous intrathecal infusion into the lumbar spinal cord
region. The 100 μl volume minipump is designed with a
0.51 μl/hr infusion rate. The minipumps were filled with
artificial cerebrospinal fluid (CSF) with 10% dimethyl
sulfoxide (DMSO) with or without SB203580 (1 mg/ml,
EMD Chemicals, Gibbstown, NJ). The minipumps were
implanted into the dorsal subcutaneous space between
the shoulder blades of each mouse at 7 wk of age under
sterile conditions. A caudally directed polyethylene can-
nula (Becton Dickinson and Company, Sparks, MD) was
threaded subcutaneously at the level of the L5 spinal
process. The L5 spinal process was removed and the tip
of the cannula was then inserted into the subarachnoid
space at the L5 level. The intrathecal infusion lasted for
1 wk at which time the mice reached 8 wk of age. Beha-
vior studies were performed, followed by tissue
collection.
Data presentation and statistical analyses
All data are presented as group means ± SEM. The data
between db+ and db/db mice of the same age were
analyzed using the Mann-Whitney test. Statistical com-
parisons between different age groups were made by
o n e - w a yA N O V At e s t sf o l l o w e db yap o s th o cT u k e y ’s
multiple comparison test. A p-value of less than 0.05
was considered statistically significant.
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